Marex Group’s Axsome Therapeutics AXSM Stock Holding History

Marex Group’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,062	Closed	-$215K	–	859
2025 Q2	$215K	Buy	+2,062	New	+$218K	﹤0.01%	520

Other funds holding AXSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Marex Group's AXSM Position: Q3 2025 in Review

Marex Group sold out of Axsome Therapeutics (AXSM) in Q3 2025, closing a stake of 2,062 shares — an estimated $215K sold.

Marex Group first reported a position in AXSM in Q2 2025 and held it in 1 quarter. The position peaked at $215K in Q2 2025. 355 funds tracked by Wall St. Rank hold AXSM as of Q3 2025.

Marex Group reported no remaining Axsome Therapeutics position as of Q3 2025 after selling out during the quarter.
Marex Group sold 2,062 Axsome Therapeutics shares in Q3 2025, an estimated $215K.
Marex Group first reported a position in Axsome Therapeutics in Q2 2025 and held it in 1 quarter.
Marex Group's Axsome Therapeutics position peaked at $215K in Q2 2025.
355 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2025.

Based on Marex Group's 13F filing for Q3 2025, filed 14 Nov 2025.